Development of a Recombinant Chimeric Antigen Expressing Different Epitopes of <i>Leishmania</i> spp. For Diagnosis of Human Cutaneous Leishmaniasis

ABSTRACT Development of highly sensitive and specific diagnostic tests for cutaneous leishmaniasis (CL) remains a significant challenge. Localized immune response in dermal leishmaniasis results in low systemic antibody production. Consequently, serologic diagnostic platform should focus on detecting Leishmania antigens directly from the skin lesions. Designing multiepitope‐based proteins as an alternative to crude antigens can enhance sensitivity and specificity, lower production costs, and facilitate development of more field‐amenable diagnostic tools. A chimeric multiepitope protein construct (THAG) was designed from four Leishmania spp. genes ( txnpx , gp63 , hsp70 , and amastin ). Bioinformatic tools were employed to ensure that the construct was optimized for expression in Escherichia coli and had favorable physicochemical properties. The gene was synthesized, subcloned into the pET28a(+) vector, and expressed in E. coli BL21 (DE3). Protein purification was carried out using Ni‐NTA affinity chromatography under hybrid conditions. The purified protein was used to generate polyclonal antibodies in rabbits, and the immunoreactivity of antiserum was assessed against Leishmania antigens from lesions of 54 volunteers with suspected active skin lesions mimic CL through an in‐house ELISA. The THAG multiepitope recombinant protein of Leishmania has successfully designed, expressed, purified and confirmed in our study. The results demonstrated sensitivity, specificity and accuracy of the ELISA test in detection of Leishmania antigens in CL lesions to be 90.91% (75.67%–98.08%), 95.24% (76.18%–99.88%), and 92.59% (82.11%–97.94%), respectively. This multiepitope protein has the potential to be further evaluated as a diagnostic tool for CL patients. While we have evaluated this multiepitope protein in an ELISA format, it might be applied to other test formats especially in immunochromatographic assays for the rapid detection of Leishmania antigens in skin lesions. Furthermore, it has the potential to be used as a tool to detect anti‐ Leishmania antibodies in serum samples of canine and human visceral leishmaniasis (VL) patients.

Authors

Institutions

Publication Details

Journal
Biotechnology and Applied Biochemistry
Published
2026-03-29
DOI
https://doi.org/10.1002/bab.70159
Primary Topic
Research on Leishmaniasis Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of a Recombinant Chimeric Antigen Expressing Different Epitopes of Leishmania spp. For Diagnosis of Human Cutaneous Leishmaniasis

Mahmoud Nateghi Rostami, Jalal Babaie, Negin Elahirad, Sahel Hamzehpour et al.
Biotechnology and Applied Biochemistry
Research on Leishmaniasis Studies
article

Development of a Recombinant Chimeric Antigen Expressing Different Epitopes of Leishmania spp. For Diagnosis of Human Cutaneous Leishmaniasis

Mahmoud Nateghi Rostami, Jalal Babaie, Negin Elahirad, Sahel Hamzehpour, Jafar Amani, Zohreh Askarypour
article en

Abstract

ABSTRACT Development of highly sensitive and specific diagnostic tests for cutaneous leishmaniasis (CL) remains a significant challenge. Localized immune response in dermal leishmaniasis results in low systemic antibody production. Consequently, serologic diagnostic platform should focus on detecting Leishmania antigens directly from the skin lesions. Designing multiepitope‐based proteins as an alternative to crude antigens can enhance sensitivity and specificity, lower production costs, and facilitate development of more field‐amenable diagnostic tools. A chimeric multiepitope protein construct (THAG) was designed from four Leishmania spp. genes ( txnpx , gp63 , hsp70 , and amastin ). Bioinformatic tools were employed to ensure that the construct was optimized for expression in Escherichia coli and had favorable physicochemical properties. The gene was synthesized, subcloned into the pET28a(+) vector, and expressed in E. coli BL21 (DE3). Protein purification was carried out using Ni‐NTA affinity chromatography under hybrid conditions. The purified protein was used to generate polyclonal antibodies in rabbits, and the immunoreactivity of antiserum was assessed against Leishmania antigens from lesions of 54 volunteers with suspected active skin lesions mimic CL through an in‐house ELISA. The THAG multiepitope recombinant protein of Leishmania has successfully designed, expressed, purified and confirmed in our study. The results demonstrated sensitivity, specificity and accuracy of the ELISA test in detection of Leishmania antigens in CL lesions to be 90.91% (75.67%–98.08%), 95.24% (76.18%–99.88%), and 92.59% (82.11%–97.94%), respectively. This multiepitope protein has the potential to be further evaluated as a diagnostic tool for CL patients. While we have evaluated this multiepitope protein in an ELISA format, it might be applied to other test formats especially in immunochromatographic assays for the rapid detection of Leishmania antigens in skin lesions. Furthermore, it has the potential to be used as a tool to detect anti‐ Leishmania antibodies in serum samples of canine and human visceral leishmaniasis (VL) patients.

Biotechnology and Applied Biochemistry
Baqiyatallah University of Medical Sciences (IR), Pasteur Institute of Iran (IR)
Openalex Percentile: Top 3%
Research on Leishmaniasis Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.